

1  
2  
3  
4  
5  
6 **MECHANISMS AND PHENOTYPES OF**  
7 **HYPERTENSION IN PATIENTS IN**  
8 **CHRONIC HEMODIALYSIS**  
9  
10  
11

12 **NCT06764277**  
13  
14  
15 **DATE: 09/11/2025**  
16  
17  
18 **INFORMED CONSENT FORM**  
19



20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70

## **INFORMED CONSENT FOR PARTICIPATING IN THE RESEARCH PROJECT**

Mechanisms and Phenotypes of Hypertension in Patients in Chronic Hemodialysis  
Clinical Trials.gov Protocol NCT06764277

**Principal Investigator:** Dr. Bernardo Rodríguez-Iturbe  
**Co-investigators:** Dr. Ricardo Correa Rotter, Dr. Eduardo Ríos Argaiz, Dra. Olynka Vega, Dra Angeles Espinosa Cuevas,  
**Address:** Vasco de Quiroga No 15, Colonia Belisario Domínguez Sección XVI, Delegación Tlalpan, México, D.F.  
**Contact telephone of the investigators:** +52.19991490061 (Dr. Rodríguez-Iturbe), +52.15579597066 (Ricardo Correa-Rotter), +52.5518437638, (Dr. Eduardo Ríos Argaiz)  
**Location of the study:** Department of Nephrology and Mineral Metabolism, Chronic Dialysis Unit, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán".  
**Address of supporting institution:** Vasco de Quiroga No 15, Colonia Belisario Domínguez Sección XVI, Delegación Tlalpan, México, D.F.

### **INTRODUCTION:**

This document is an invitation to participate in a research project of the institution. Please take all the time you need to read this document and ask the investigator to clarify any doubts you have.

You have the right to decide if you want to participate as a subject of research in this project. The investigator must explain to you the benefits and risks **without any pressure and you will have al the time you require to think, by yourself or with anyone you decide to consult, before deciding if you accept to participate.** Whatever your decision may be, it will have no effect over the medical care you will receive in the institution,

In order for you to take a truly informed decision about accepting or not to participate in this study you need to have sufficient knowledge about the possible health risks and benefits of your participation. This document will give you detailed information about the investigation, which you are free to comment with anyone you desire, for example, a family member, your personal physician, the principal investigator of the study or any member of the research team. Once read and understood the information you will be invited to be part of the project and if you accept without any pressure or intimidation, you will be invited to sign this informed consent.

This informed consent is made in accordance with the requisites established in Regulation of the General Health Law in the subject of Investigation for Health, the Helsinki Declaration and the Good Clinical Practice guidelines of the National Bioethical Commission.

At the end of the informed consent procedure, you should understand the following aspects: .

- I. The justification and the aims of the investigation.
- II. The procedures that will be used and their purpose, including the identification that they are

- III. experimental procedures.
- IV. The risks and the inconveniences involved.
- IV. The potential benefits.
- V. The alternative procedures that may be to your advantage.
- VI. The warranty to receive answers to your questions and clarification of any doubts on the procedures, risks, benefits, and other aspects related to investigation and the area of investigation and its treatment.
- VII. You are free to withdraw your consent at any time and cease your participation in the study and this decision will not have any effect on your medical care and treatment in the institution.
- VIII. You should be sure that you will not be identified in a specific form and your private information will be confidential.
- IX. The investigator will give you the up-to-date information obtained during the study, even this information could affect your disposition to continue to participate in the study.
- X. You are assured to have the medical treatment and compensation that you are entitled to have if there are damages caused directly for the investigation.

**You can ask for more time, or to take home this document, before making a final decision in in future days.**

**INVITATION TO PARTICIPATE AS A SUBJECT OF INVESTIGATION IN THE PROJECT**  
Mechanisms and Phenotypes of Hypertension in Patients in Chronic Hemodialysis  
Clinical Trials.gov Protocol NCT06764277

Dear Mr., Miss, Mrs.

The Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), through the research group, invites you to participate as a subject of an investigation **directed to study the relation between water overload, the renin-angiotensin system and inflammatory reactivity in the hypertension and its phenotypes in chronic hemodialysis patients.**

The study will be done by evaluations immediately after and before two successive dialysis sessions in addition to a study of ambulatory blood pressure in the interval between dialysis. There will be no alteration in the date or the hours of hemodialysis treatments. We anticipate number of participants will be 50 patients. You have been invited to participate because the study will evaluate patients in renal replacement therapy with chronic hemodialysis

## STUDY PROCEDURES

The study will not cause any change of treatment or additional treatments to your present treatment.

Your participation in the study consists in:

1. To present yourself to the hemodialysis sessions that you already have programmed.
2. In the interval between 2 dialysis there will be an ambulatory monitoring and registration of blood pressure (ABPM) with the use of an equipment that will be given to you after the first hemodialysis. You will have to bring back the equipment to the dialysis unit when you come for the next dialysis.
  - The equipment for the ABPM consists of a cuff and a registration device that records

123 the obtained data.

124 • The cuff is designed to inflate periodically and will be programmed to inflate every 30

125 minutes during the day and every hour during the night during a period of 24 hours

126 • After inflation the cuff will deflate little by little and register the blood pressure at the

127 intervals previously mentioned

128 • The recording device will store the results

129 • During the time of ABPM you should continue with normal day activities.

130 • You should keep a record of the time of your daily activities that could modify the blood

131 pressure, for example physical activity, moments of stress, and the time when you go to

132 sleep and wake up the next day. The blood pressure record will be analyzed in the

133 context of your activities

134 • The equipment you will be carrying are automatic, of light weight and silent and use the

135 oscilometric method for measuring blood pressure.

136 • The ABPM equipment will be removed by us when you come to the next dialysis

137

138 3. The day you come for dialysis blood samples will be taken for the determination of concentrations

139 of various markers of hormonal systems and inflammation related to blood pressure. The total

140 amount of blood that will be used will be 10 ml.

141 4. The additional studies will be done by ultrasound techniques you are familiar with because they

142 are used in studies of heart function and bioimpedance done routinely at your evaluation in the

143 chronic hemodialysis program.

144 The research studies do not include experimental interventions of any kind. Your treatments will not

145 be modified.

146 The responsibilities of the participants are to be present in the programmed hemodialysis treatment and

147 do the ABPM in the one (1) opportunity in the selected interval between dialysis and bring back the

148 ABPM equipment at the next dialysis.

## 152 **RISKS AND INCONVENIENCES**

153 The General Law of Health in the subject of Investigation in Health states that the obtention of

154 biological samples represent a minimal risk within investigation. In your case, blood sampling is not an

155 additional risk because the samples will be obtained from the same place and at the same time that

156 normally are taken the samples for tests done at the beginning of hemodialysis

157 Potential inconveniences of the ABPM could be derived from the repeated inflation of the cuff and a

158 relative limitation of physical activities and difficulties in peaceful sleeping. The ABPM is a safe

159 procedure without risks derived from its use.

160 The information about your identity and medical information will be protected by codification of the

161 samples and will not be revealed at any time as required by law and, therefore, you have no risk derived

162 from loss of confidentiality.

## 169 **POTENTIAL BENEFITS**

170 The study is not designed to benefit you directly.

171 There may be results of ABPM and some of the tests that may uncover important mechanisms of

172 hypertension.

175

## 176 **ECONOMIC CONSIDERATIONS**

177

178 The studies will have no cost for the patient. se le and there will no be any payment for participation.

179

180

181

## 182 **COMPENSATION**

183

184 If there is any complication directly related to the participation in the study the institution will provide  
immediate treatment and, if indicated, referral to the appropriate medical specialist.

185

186

## 187 **ALTERNATIVES TO YOUR PARTICIPATION**

188

189 Your participation is voluntary. If you decide not to participate you will continue to receive the

190

## 191 **COMMERCIAL PRODUCTS DERIVED FROM THE STUDY**

192

193 Any material of commercial interest derived from the study will be property of the INCMNSZ

194

195 You can ask for your results of the study after its completion to Bernardo Rodríguez Iturbe, or to Dr.  
196 José Ricardo Correa Rotter. Please remember that research is long and complex process and we  
197 cannot predict when definite results may be expected.

198

199

200 **IF YOU DECIDE TO STOP YOUR PARTICIPATION IN THE STUDY** The procedure is to notify your  
201 decision the investigator(s) and if you desire that your data be retired and the samples destroyed you  
202 can ask for it in writing.

203

204 **YOU MAY BE EXCLUDED FROM THE STUDY** if you miss appointments or do not perform the ABPM  
205 or other programmed studies.

206

207

## 208 **CONFIDENTIALITY IN HANDLING YOUR PERSONAL DATA**

209

210 Your name will not be used in any of the public reports of the study. All your samples will be handled  
211 with codes to avoid possible identification. Is possible that your biological samples may be used in  
212 other research projects but if this possibility arises, the decision will made by the ethical committee,

213

214 Your biological samples will be stored for up to 5 years.

215

216 The ethical committee of the INCMNSZ approved this study. In the future if we identify information that  
217 we consider of important for your health we will consult with the Ethics Committee on the best way to  
218 make this information available to you and your personal physician

219

220 The scientific data obtained as part of the study would be used in medical publications and congress.

221

222

## 223 **IDENTIFICATION OF THE INVESTIGATORS.**

224

225 If you need to clarify doubts regarding the study please contact any one of the following:

226

+52.19991490061 (Dr. Rodríguez-Iturbe), +52.15579597066 (Ricardo Correa-Rotter),

+52.5518437638, (Dr. Eduardo Ríos Argaz)

227 I you have questions regarding your rights as participant of the study please contact the President of  
228 the Ethics of Investigation Committee of the INCMNSZ (Dr. Arturo Galindo Fraga, telephone: 54870900  
229 ext. 6101).

230

231

232

233

234

## DECLARATION OF INFORMED CONSENT

235 I have carefully read this informed consent document; have made all the questions I wanted and they  
236 have been answered to my satisfaction. In order to participate in the study, I make known that the  
237 general and specific purposes of recruitment and the possible injury and inconveniences of the study  
238 have been explained to me at my complete satisfaction.

239

240 I agree to voluntarily donate mis biological samples (urine and blood) to be used for the study. In  
241 addition, all my medical and biological information could be used in the study for the purposes of the  
242 study.

243

244 I agree, in case is necessary, to be contacted in the future if the study if the study requires the collection  
245 of additional information that is relevant for my health.

246

247 My signature indicates that I have received a duplicate of this consent form.

248

249

250 Please answer the following questions:

251

252

	YES	NO
a. Have you read and understood the informed consent form in your own language?	<input type="checkbox"/>	<input type="checkbox"/>
b. Have you had the opportunity to ask questions and discuss the study?	<input type="checkbox"/>	<input type="checkbox"/>
c. Have you received satisfactory answers to all your questions?	<input type="checkbox"/>	<input type="checkbox"/>
d. Have you received sufficient information and had enough time to make a decision?	<input type="checkbox"/>	<input type="checkbox"/>
e. Do you understand that your participation is voluntary and you are free to cancel your participation in the study at any time without having to justify your decision without your decision affecting your medical attention or loss of benefits that you may be otherwise entitled ?	<input type="checkbox"/>	<input type="checkbox"/>
f. Do you authorize access to your medical information to principal investigator or his/her representatives, auditors and regulatory committees and Mexican government instances that regulate the study?	<input type="checkbox"/>	<input type="checkbox"/>
g. Do you understand the potential risks, some of them unknown, to participate in the study?	<input type="checkbox"/>	<input type="checkbox"/>
h. Do you understand that you may not receive any direct benefit for your participation in the study?	<input type="checkbox"/>	<input type="checkbox"/>

		YES	NO
i.	Have you discussed other potential treatment options and understand that these options are available to you?	<input type="checkbox"/>	<input type="checkbox"/>
j.	¿Entiende que no está renunciando a ninguno de sus derechos legales a los que es acreedor de otra forma como sujeto en un estudio de investigación? (NOT APPLICABLE)	<input type="checkbox"/>	<input type="checkbox"/>
k.	Do you understand that investigators may take you out of the study without your consent because you did not follow the requirements and also your personal physician if he considers that your retirement is to your best interest??	<input type="checkbox"/>	<input type="checkbox"/>
l.	Do you understand that the institution and sponsors may stop the study at any time?	<input type="checkbox"/>	<input type="checkbox"/>
m.	Do you understand that you will receive an original signed copy of the consent form for your personal file?	<input type="checkbox"/>	<input type="checkbox"/>

253

254

255

256

257

258

259

260

261

262

263 **Declaration of the patient:**

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

I, \_\_\_\_\_ declare that is my decision to participate in the study. My participation is voluntary.

I have been informed that I can refuse to participate or cease my participation at any time without any penalty or loss of benefits. If I stop my participation, I will nevertheless receive the treatment that I have a right to receive in the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ). I may ask for additional information about risks and benefits of the study and obtain the results of my clinical tests if I ask for them. To ask any questions of information concerning the study may be obtained from Bernardo Rodríguez Iturbe (+52.19991490061), Ricardo Correa Rotter (+52.15579597066) o Eduardo Ríos Argaiz (+52.5518437638)

I have to inform the investigators of any change in my health or medications or change of address that may take place, as soon as possible.

I have read and understood all the information I received related to my participation in the study. I had the opportunity to discuss and ask questions about the study and they have been answered to my satisfaction.

I have been informed that if I have further questions about the study and my rights, I am at liberty to contact the President of the Committee of Research of the INCMNSZ Dr. Arturo Galindo Fraga, (Tel. 54870900 ext. 6101).

289  
290  
291  
292

---

293 Name of the Participant

---

Signature of the Participant

294  
295  
296

---

297 Date

300  
301

302 Place digital mark of the participant here if he/she does not know how to write

303  
304

---

305 Name of the legal representative (if applicable)

---

Signature

306  
307  
308

---

309 Date

310  
311  
312  
313  
314

---

315 Name of investigator that explained this document

---

Signature

316  
317  
318  
319

---

320 Date

321  
322  
323

---

324 Name of witness 1

---

Signature of Witness 1

325  
326  
327

---

328 Date

---

Relation with participant

329  
330

331 Address: \_\_\_\_\_

332  
333  
334

---

335 Name of witness 2

---

Signature of Witness 2

336  
337  
338  
339  
340

342 \_\_\_\_\_

343 Date \_\_\_\_\_

344 \_\_\_\_\_

345 \_\_\_\_\_

346 Address \_\_\_\_\_

347 \_\_\_\_\_

348 \_\_\_\_\_

349 \_\_\_\_\_

350 \_\_\_\_\_

351 Place and Date : \_\_\_\_\_

352 \_\_\_\_\_

353 \_\_\_\_\_

354 \_\_\_\_\_